Sanofi, Regeneron start cholesterol trials

Friday 20 July 2012

Sanofi SA and Regeneron Pharmaceuticals Inc have started enrolling patients in a Phase 3 programme that will evaluate the effectiveness of a new antibody in lowering low-density lipoprotein cholesterol. The antibody targets the PCSK9 enzyme.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

France